New SteriPort production line commissioned at Kheda facility

Capex & Operations View source PDF Explain this filing

AMANTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹188.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+0.6% vs market

Pharmaceuticals peers, median of 172sector+0.3%+0.9% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2+0.6+0.6+0.3+0.9

Next day

+3.2+1.3+1.9+0.2+3.0

+5.3+1.7+3.6+0.8+4.5

+7.4+2.2+5.1+1.1+6.3

+9.5+2.1+7.4+0.6+8.9

+7.3+1.9+5.4+0.8+6.6

+3.1-1.3+4.4-1.1+4.2

15d

-1.1+1.3-2.4+0.8-1.9

+6.3-0.8+7.2-2.2+8.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Amanta Healthcare has commenced production at its new SteriPort facility at the Kheda campus. SteriPort is a sterile IV container line featuring two-port leak-proof design, superior compatibility with oncology and ICU drugs, and higher automation. The brownfield expansion targets reduced manual handling and improved quality. Management expects the new line to scale up operational and financial efficiency, resulting in EBITDA margin expansion.

Likely market impact

Positive - expected EBITDA margin expansion and improved operational efficiency from the new sterile IV manufacturing capacity.